Immunoelectrophoresis Patents (Class 436/516)
  • Patent number: 10330690
    Abstract: The application describes methods for determining the concentration and/or particle number of a lipoprotein(a) subform in a biological sample using capillary isotachophoresis laser induced fluorescence (CE-ITP-LIF) and compositional analysis of lipoprotein(a) particles. The ability to measure the concentration and/or particle number of a lipoprotein(a) subform in a biological sample provides a useful diagnostic tool for assessing cardiovascular risk in a subject.
    Type: Grant
    Filed: October 27, 2015
    Date of Patent: June 25, 2019
    Assignee: HELENA LABORATORIES CORPORATION
    Inventors: Philip Guadagno, Erin Grace (Summers) Bellin
  • Patent number: 9733241
    Abstract: Provided herein are compositions useful in detecting degradative enzymes and biomolecules in bodily fluid samples.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: August 15, 2017
    Assignee: The Regents of the University of California
    Inventors: Michael Heller, Geert W. Schmid-Schoenbein, Roy B. Lefkowitz, Benjamin Sullivan
  • Patent number: 9488666
    Abstract: An assembly, method, system, and apparatus for the assessment of the level of specific lipoprotein particles present in a bodily fluid are disclosed. The levels determined may be used to predict the risk of developing various diseases related to lipoprotein particles.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: November 8, 2016
    Assignee: Helena Laboratories Corporation
    Inventors: Philip Angelo Guadagno, Debra Linn Hicks, Joseph Paul McConnell
  • Patent number: 8962269
    Abstract: The present invention relates to the discovery of the human survival motor-neuron gene or SMD gene, which is a chromosome 5-SMA (Spinal Muscular Atrophy) determining gene. The present invention further relates to the nucleotide sequence encoding the SMN gene and corresponding amino acid sequence, a vector containing the gene encoding the SMN protein or a DNA sequence corresponding to the gene and transformant strains containing the SMN gene or a DNA sequence corresponding to the gene.
    Type: Grant
    Filed: February 4, 2013
    Date of Patent: February 24, 2015
    Assignee: Institut National de la Sante et de la Recherche Medicale
    Inventors: Judith Melki, Arnold Munnich
  • Publication number: 20150050749
    Abstract: The invention provides a method for detection of mutant-type DNA or/and wild-type DNA by contacting at least one of a single-stranded DNA having a substituted nucleotide, a deficient nucleotide region, or an inserted nucleotide region (mutant-type DNA), or/and a wild-type single-stranded DNA corresponding to the mutant-type DNA (wild-type DNA) with a probe hybridizing with both single-stranded DNAs, to form a hybrid with the mutant-type DNA (mutant-type hybrid) or/and a hybrid with the wild-type DNA (wild-type hybrid) (at least one of the obtained mutant-type hybrid and wild-type hybrid has a loop structure), (2) contacting the obtained mutant-type hybrid or/and wild-type hybrid with an intercalator, and (3) detecting the presence or absence of the mutant-type DNA or/and the wild-type DNA by separating the conjugate of mutant-type hybrid and intercalator or/and the conjugate of wild-type hybrid and intercalator.
    Type: Application
    Filed: March 22, 2013
    Publication date: February 19, 2015
    Applicants: WAKO PURE CHEMICAL INDUSTRIES, LTD., KANAGAWA PREFECTURAL HOSPITAL ORGANIZATION
    Inventors: Shoichi Matsukuma, Tomokazu Ishikawa, Tatsuo Kurosawa
  • Patent number: 8921123
    Abstract: Microfluidic devices and methods for using the same are provided. Aspects of the invention include microfluidic devices that include a separation medium and a pan-capture binding medium. The microfluidic devices are configured to subject a sample to two or more directionally distinct electric fields. Also provided are methods of using the devices as well as systems and kits that include the devices. The devices, systems and methods find use in a variety of different applications, including diagnostic and validation assays.
    Type: Grant
    Filed: November 22, 2011
    Date of Patent: December 30, 2014
    Assignee: The Regents of the University of California
    Inventors: Amy E. Herr, Dohyun Kim
  • Patent number: 8889102
    Abstract: The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).
    Type: Grant
    Filed: September 19, 2008
    Date of Patent: November 18, 2014
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vanda A. Lennon, Sean J. Pittock
  • Publication number: 20140308277
    Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
    Type: Application
    Filed: April 15, 2014
    Publication date: October 16, 2014
    Applicant: GENENTECH, INC.
    Inventors: Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
  • Patent number: 8741600
    Abstract: A method of accurately separating immunoglobulin monomers by subjecting an immunoglobulin solution containing at least immunoglobulin monomers and immunoglobulin aggregates to cross-flow filtration using an ultrafiltration membrane, an ultrafiltration membrane module, and a cross-flow filtration apparatus. The method can separate immunoglobulin monomers by subjecting an immunoglobulin solution containing at least immunoglobulin monomers and immunoglobulin aggregates and having an immunoglobulin concentration of 1 to 150 g/L to cross-flow filtration using an ultrafiltration membrane having a molecular weight cut-off of 100,000 or more and less than 500,000 so that immunoglobulin monomers passes through the ultrafiltration membrane with a permeability of 80% or more while achieving a fractionation performance in which the permeability ratio of immunoglobulin dimers to immunoglobulin monomers that pass through the ultrafiltration membrane is 0.20 or less.
    Type: Grant
    Filed: June 18, 2008
    Date of Patent: June 3, 2014
    Assignee: Asahi Kasei Kabushiki Kaisha
    Inventors: Fumihiko Yamaguchi, Hitoshi Mizomoto, Shinya Hamasaki, Takena Mochizuki
  • Patent number: 8609435
    Abstract: A method for capillary electrophoretic analysis of a biological sample, comprising using negatively surcharged modified antibodies so that they migrate to a zone located outside the migration zone for proteins from the biological sample when they are separated during electrophoresis is disclosed. The antibodies have antigenic specificity for a predetermined target protein.
    Type: Grant
    Filed: November 9, 2004
    Date of Patent: December 17, 2013
    Assignee: SEBIA
    Inventors: Frédéric Robert, Régis Andre
  • Patent number: 8507208
    Abstract: Provided herein are microfluidic devices and methods useful for sensitive detection of analytes. The methods and devices described herein are also useful for detecting direct or indirect binding of enzymes or catalysts to a surface, for example a surface having analytes bound thereon. Methods disclosed herein include embodiments utilizing a pre-concentration scheme to improve signal levels of corresponding reporter moieties.
    Type: Grant
    Filed: July 23, 2010
    Date of Patent: August 13, 2013
    Assignee: University of Wyoming
    Inventors: Robert C. Corcoran, Debashis Dutta
  • Patent number: 8486401
    Abstract: Monoclonal antibodies, synthetic and biotechnological derivatives thereof (ScFv or others) are able to recognise the NGF high affinity receptor, TrkA, and act as NGF-antagonist molecules. Pharmacological compositions for therapy, gene therapy, diagnostics of neurological pathologies are also described. Transgenic animal models to study such pathologies are also described.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: July 16, 2013
    Assignee: Lay Line Genomics S.p.A.
    Inventor: Michal M. Novak
  • Patent number: 8105844
    Abstract: An apparatus includes a porous membrane for retaining antigens from a sample as the sample passes through the membrane. The apparatus also includes a first binding region within the membrane. The first binding region includes antibodies associated with a first antigen of interest. At least some of the antigens retained in the membrane are brought into contact with the first binding region by applying an electrophoresis field across the membrane. The porous membrane could also include an electrophoresis buffer. A presence of the first antigen of interest could be detected by exposing the first binding region to a chemiluminescent reagent, and a quantity of the first antigen of interest could be determined by performing a chemiluminescent assay on the binding region.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: January 31, 2012
    Assignee: Honeywell International Inc.
    Inventors: Zhen Hong Sun, Tao Pan, Wendy Wang, Xuanbin Liu
  • Patent number: 8088579
    Abstract: The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD.
    Type: Grant
    Filed: February 14, 2006
    Date of Patent: January 3, 2012
    Assignee: University of Iowa Research Foundation
    Inventors: Gregory S. Hageman, Richard J. Smith
  • Patent number: 7998683
    Abstract: Measurement of circulating ST2 and/or IL-33 concentrations is useful for the prognostic evaluation of subjects, in particular for the prediction of adverse clinical outcomes, e.g., mortality, and the detection of severe disease.
    Type: Grant
    Filed: April 24, 2007
    Date of Patent: August 16, 2011
    Assignee: Critical Care Diagnostics, Inc.
    Inventors: James V. Snider, Sven Jacobson
  • Publication number: 20110195478
    Abstract: The present invention discloses a bladder cancer biomarker and a test method using the same. The biomarker contains at least one of the mentioned 69 compounds, such as apolipoprotein A1 (APOA1), apolipoprotein A2 (APOA2), peroxiredoxin 2 (PRDX2), heparin cofactor 2 precursor (HCII), and serum amyloid A-4 protein (SAA4), which exist in the urine specimen of a testee. The expression intensity of the biomarker can facilitate diagnosis of bladder cancer and evaluation of aggressiveness and malignancy of bladder cancer. Thereby, the physician can arrange an optimized treatment to achieve the best therapeutic effect.
    Type: Application
    Filed: August 4, 2010
    Publication date: August 11, 2011
    Inventors: Yi-Ting Chen, Jau-Song Yu, Chien-Lun Chen, Yu-Sun Chang
  • Patent number: 7947254
    Abstract: The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).
    Type: Grant
    Filed: July 14, 2006
    Date of Patent: May 24, 2011
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Vanda A. Lennon, Thomas J. Kryzer
  • Publication number: 20100303832
    Abstract: The invention relates to genes, gene polymorphisms, and genetic profiles associated with an elevated or a reduced risk of alternative complement cascade deregulation disease such as AMD. The invention provides methods and reagents for determination of risk, diagnosis and treatment of such diseases. In an embodiment, the present invention provides methods and reagents for determining sequence variants in the genome of a patient which facilitate assessment of risk for developing such diseases.
    Type: Application
    Filed: November 3, 2008
    Publication date: December 2, 2010
    Inventor: Gregory S. Hageman
  • Patent number: 7838285
    Abstract: Apparatus and method employing gel electrophoresis and optical imaging techniques to measure the amount of biomaterial that attaches to specified locations on a detector slide and to determine the molecular weight of the molecules at those locations.
    Type: Grant
    Filed: April 24, 2006
    Date of Patent: November 23, 2010
    Assignee: Maven Biotechnologies LLC
    Inventors: Shane Dultz, David Ralin, William Rassman
  • Patent number: 7824923
    Abstract: The invention relates to novel neuregulin-? isoforms associated with neuronal processes.
    Type: Grant
    Filed: August 6, 2002
    Date of Patent: November 2, 2010
    Assignee: ProteoSys Ag
    Inventor: André Schrattenholz
  • Patent number: 7736621
    Abstract: The invention provides a diagnostic composition for detecting an affective disorder comprising an antibody selected from the group consisting of an antibody to a beta-arrestin, an antibody to a G-protein coupled receptor kinase and combinations thereof as the active detecting agent therein.
    Type: Grant
    Filed: August 3, 2005
    Date of Patent: June 15, 2010
    Assignee: Hypatia Ltd.
    Inventors: Sofia Avissar, Gabriel Schreiber
  • Publication number: 20100135988
    Abstract: A method of detecting proliferative diseases causing sclerosis, comprising measuring the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1, phosphorylated Smad1, activin receptor-like kinase 1, activin receptor-like kinase 3 and bone morphogenetic proteins in a biological sample. A kit therefor. A prophylactic and/or therapeutic agent for proliferative diseases causing sclerosis, comprising as an active ingredient a substance having an inhibitory effect on the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A method of identifying substances effective in preventing and/or treating proliferative diseases causing sclerosis, comprising judging whether or not a test substance inhibits the expression of at least one substance selected from the group consisting of STAT3, phosphorylated STAT3, Smad1 and phosphorylated Smad1. A kit therefor.
    Type: Application
    Filed: September 28, 2009
    Publication date: June 3, 2010
    Inventors: Toshio Doi, Hideharu Abe
  • Patent number: 7723042
    Abstract: The present invention relates to novel methods and devices for differentiating in a patient parathyroid diseases, such as hyperparathyroidism and related bone diseases, from normal or non-disease states. One detects whole or non-fragmented (1 to 84) parathyroid hormone in a biological sample and also a large non-whole parathyroid hormone peptide fragment that can function as a parathyroid hormone antagonist. By either comparing values or using independently the value of either the large non-whole parathyroid hormone peptide fragment, the whole parathyroid hormone, or the combination of these values one is able to differentiate parathyroid and bone related disease states, as well as differentiate such states from normal states.
    Type: Grant
    Filed: September 20, 2004
    Date of Patent: May 25, 2010
    Assignee: Scantibodies Laboratory, Inc.
    Inventors: Thomas L. Cantor, Ping Gao
  • Patent number: 7604948
    Abstract: The present invention provides methods of identifying biomarkers indicative of the presence of a neurodevelopmental disorder, including an autism spectrum disorder, in an individual, using cytometry and mass spectrometry. The invention further provides methods of using the identified biomarkers to diagnose the presence of a neurodevelopmental disorder, including an autism spectrum disorder.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: October 20, 2009
    Assignee: The Regents of the University of California
    Inventors: David G. Amaral, Blythe A. Corbett
  • Publication number: 20090181472
    Abstract: The present invention discloses a labeled molecule for prognosing the tumor grade of head neck cancer and a method for the same, wherein a 78-kDA glucose regulated protein (GRP78) is adopted as a labeled molecule of head neck cancer. GRP78 is much more overexpressed in head neck cancer cells than in non-cancer cells. GRP78 also has relation with tumor size, tumor depth and tumor metastasis. Therefore, the present invention uses GRP78 overexpression as a reference for tumor grading of head neck cancer.
    Type: Application
    Filed: May 8, 2008
    Publication date: July 16, 2009
    Inventors: Ann-Joy CHENG, Joseph T. Chang, Ching-Chi Chiu
  • Publication number: 20090081345
    Abstract: The present invention relates to the use of milk or a derivative thereof for identifying prion proteins, preferably PrPSc prion proteins, in a mammal. The present invention is also directed to a method for identifying prion proteins, preferably PrPSc prion proteins, in mammals, comprising the step of contacting milk or a derivative thereof with an agent having high affinity and selectivity for prion proteins, preferably for PrPSc prion proteins. In addition, a further aspect the present invention concerns a method for removing PrPC and/or PrPSc prion proteins, preferably PrPSc prion proteins, from milk or a milk derivative wherein milk or a derivative thereof is contacted with sepharose, preferably sepharose comprising divalent immobilized metal ions.
    Type: Application
    Filed: April 30, 2007
    Publication date: March 26, 2009
    Applicant: ALICON AG
    Inventors: Ralph Zahn, Nicola Franscini, Ahmed El Gedaily
  • Patent number: 7482128
    Abstract: The present invention provides isolated monoclonal antibodies that selectively bind albumin from animals. Also provided are methods using such antibodies for the detection of early renal disease in animals. The method includes the steps of (a) obtaining a sample from an animal to be tested; (b) contacting the sample with an antibody having a greater avidity for feline albumin than for other proteins or components in the sample; (c) detecting the complex formed by the antibody and albumin; and (d) determining the amount of albumin in the sample from the amount of antibody-albumin complex detected. An amount of albumin in the range of from 10 ?g/ml to about 300 ?g/ml indicates the presence of early renal disease.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: January 27, 2009
    Assignee: Heska Corporation
    Inventors: Wayne A. Jensen, Shirley Wu Hunter, Karen Sverlow, Janet S. Andrews
  • Patent number: 7462495
    Abstract: Methods are provided for diagnosing and/or characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence of low molecular actin fragments. The assay results are used to diagnose the presence of chronic immune disease activity and/or characterize chronic immune disease activity in the subject, e.g. to confirm an initial chronic immune disease diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. Also provided by the subject invention are kits for practicing the methods.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: December 9, 2008
    Assignee: R.E.D. Laboratories N.V.
    Inventors: Simon Adriaan Michiel Roelens, Patrick Englebienne, Anne Marie Yvonne Robert D'Haese, Charles Vincent Taylor Herst
  • Publication number: 20080220459
    Abstract: A method for detecting or monitoring the presence of protein fragments, cleaved at novel cleaving sites near the N-terminal part of the collagen IX alpha 1 chain, close to the C-terminal part of the NC4 domain, and at the COL3 domain close to the NC3 domain. Neoepitope antibodies against the neoepitopes were created by the cleavages and an epitope in the cleaved N-terminal part of the NC4 domain unique to collagen IX.
    Type: Application
    Filed: February 26, 2008
    Publication date: September 11, 2008
    Inventors: Mikael Danfelter, Patrik Onnerfjord, Dick Heinegard
  • Patent number: 7407764
    Abstract: This invention provides the first blood test which characterizes asthma severity. More specifically, the present invention provides methods of determining the severity of acute asthma in a patient by determining the levels of C5a or C5a-desArg in the patient's blood, plasma or serum.
    Type: Grant
    Filed: October 17, 2005
    Date of Patent: August 5, 2008
    Assignee: The Research Foundation of State University of New York
    Inventors: Rauno Joks, Hazel P. Drew, Myrelle B. Castro, Nandita Mathur Khaneja
  • Patent number: 7217574
    Abstract: Performing high-resolution determination of the relative shift of the spectral properties of a biosensor. The shift in the resonance peak of the biosensor is indicative of the amount of material bound to the surface of the biosensor. A preferred biosensor is a Guided Mode Resonant Filter Biosensor (GMRFB). In one aspect of the invention, curve fitting is used to determine the relative location of the spectrum of the unexposed biosensor with respect to those spectra that are altered (e.g., shifted) by the presence of materials bound to the surface of the biosensor. In an alternative embodiment, the cross correlation function is used to detect spectral peak offsets between a reference spectrum and a spectrum measured from an exposed biosensor. In yet another alternative, maximal likelihood estimation techniques are used to determine the spectral shift or offs.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: May 15, 2007
    Assignee: SRU Biosystems, Inc.
    Inventors: Homer Pien, William C. Karl, Derek Puff, Peter Li, Brian Cunningham
  • Patent number: 7217505
    Abstract: The use of cortisol agonist for preparing a system for diagnosis of the metabolic syndrome and related conditions as belly fatness, insulin resistancy including increased risk of developing senile diabetes, i.e. diabetes type II, high blood fats and high blood pressure, in which system the dose of cortisol agonist is in an interval where a difference is obtained in the inhibitory effect of the autoproduction of cortisol in individuals suffering from the metabolic syndrome, compared to normal values.
    Type: Grant
    Filed: June 25, 2002
    Date of Patent: May 15, 2007
    Assignee: Cortendo AB
    Inventor: Per Marin
  • Patent number: 7202044
    Abstract: The invention relates to defined peptides and the quantitative determination thereof in body fluids of patients suffering from progredient chronic dementia, in relation to the concentration of said peptides in a control group. The inventive peptides come from a protein precursor having the corresponding gene, are processed in a specific manner, and are optionally post-translationally modified, especially phosphorylized. An increase in the concentrations of these peptides or the corresponding non-processed protein indicates progredient chronic dementia. Progredient chronic dementia is detected by identifying the peptides and/or the protein individually or in combinations. The invention also relates to the use of said peptides for controlling the course of progredient chronic dementia and for the prognosis of progredient chronic dementia, especially for complementing or replacing mini-mental scores, and for developing therapeutic agents to combat progredient chronic dementia such as Alzheimer's disease.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: April 10, 2007
    Assignee: Biovision AG
    Inventors: Norbert Lamping, Hans-Dieter Zucht, Harmut Selle, Michael Jürgens, Gabriele Heine, Rüdiger Hess
  • Patent number: 7179639
    Abstract: This is a self-contained disposable thermal cycler device in which target sequence is amplified as the samples passes over a grid of alternating temperature and then at the completion of the reaction, the amplified material is captured by probes complementary to the targeted sequence. Since the device can be sealed and is disposable, it reduces the occurrence of cross contamination or specimen carry-over.
    Type: Grant
    Filed: March 5, 2003
    Date of Patent: February 20, 2007
    Inventors: Raveendran Pottathil, Jerome Anton Streifel
  • Patent number: 7179612
    Abstract: A method for diagnosing a condition of a patient involves the steps of (a) adding one or more reagents to a test sample from a patient, the test samples comprising at least part of a blood sample from the patient, in order to cause formation of a complex comprising at least one acute phase protein and at least one human lipoprotein, while causing substantially no fiber polymerization; (b) measuring the formation of the complex over time so as to derive a time-dependent measurement profile, and (c) determining a slope and/or total change in the time-dependent measurement profile, so as to diagnose a condition of the patient. A greater formation of the complex is correlated to increased probability of death of the patient.
    Type: Grant
    Filed: June 8, 2001
    Date of Patent: February 20, 2007
    Assignee: bioMerieux, Inc.
    Inventors: Timothy J. Fischer, Colin Downey, Mike Nesheim, John A. Samis, Liliana Tejidor, Cheng-Hock Toh, John B. Walker
  • Patent number: 7157223
    Abstract: The activity of intracellular chemical reactions of molecules is measured by the use of fluorescently labeled substrate molecules that undergo a change in electrophoretic mobility upon chemical reaction such as that catalyzed by an enzyme. Specificity is achieved by using labeled substrate molecules that can be acted upon only by specific enzymes. Thus the activity of a specific enzyme or class of enzymes can be determined. Measurements are made with the intracellular presence of such substrate molecules, at some time of interest, typically after exposure of the cell to a stimulus that activates a particular enzymatic pathway. To ensure accuracy, measurements must be made in a timely manner so as to minimize chemical reactions occurring subsequent to the time of interest. Fast controllable laser lysis is used to obtain the contents of a single cell into which reporter substrate molecules have been introduced.
    Type: Grant
    Filed: August 30, 2001
    Date of Patent: January 2, 2007
    Assignee: The Regents of the University of California
    Inventors: Nancy Allbritton, Christopher Sims, Michael W. Berns, Gavin D. Meredith, Tatiana B. Krasieva, Bruce J. Tromberg, Chao L. Lee
  • Patent number: 7153701
    Abstract: A method for quantitatively detecting an antigen which comprises (1) a first step of providing an Fab? antibody having a uniform isoelectric point, said antibody forming an immune complex with an antigen in an analytical sample and being modified by adding an amino acid sequence comprising a charged amino acid residue and by being labeled with a fluorescent dye, (2) a second step of mixing the Fab? antibody having a uniform isoelectric point with the analytical sample containing the antigen to obtain a mixture comprising the immune complex, (3) a third step of separating the mixture by performing electrophoresis in a carrier, (4) a fourth step of irradiating an excitation light which excites the fluorescent dye to the mixture separated in the third step to cause fluorescence in the immune complex, and (5) a fifth step of detecting the fluorescence.
    Type: Grant
    Filed: February 17, 2000
    Date of Patent: December 26, 2006
    Assignee: Hamamatsu Photonics K.K.
    Inventors: Sunao Hisada, Yukiko Ito, Hiroyuki Matsumoto, Kiyohito Shimura, Kenichi Kasai
  • Patent number: 7135300
    Abstract: Methods are provided for detecting formation of oligomeric complexes of molecules on the surface of cell membranes. These methods employ pairs of tagged probes and cleaving probes, each of which binds specificly to a cell surface molecule. The tagged probe includes a molecular tag that is linked to a first binding compound through a cleavable linkage, and the cleaving probe includes a second binding agent and a cleavage-inducing moiety that can cleave the linkage when within a defined proximity thereto. Binding of the two probes to cell surface molecules that have formed an oligomeric complex results in release of the molecular tag from the binding compound, providing a measure of formation of the complex.
    Type: Grant
    Filed: April 22, 2004
    Date of Patent: November 14, 2006
    Assignee: Monogram Biosciences, Inc.
    Inventors: Po-Ying Chan-Hui, Yining Shi, Sailaja Pidaparthi, Rajiv Dua, Sharat Singh
  • Patent number: 7115422
    Abstract: A sample separation apparatus including a porous, or rough, capillary column. The porous capillary column includes a matrix which defines pores, and may be formed rough surface of hemispherical grain silicon. The capillary column is defined in a surface of a substrate, such as silicon. The sample separation apparatus may include a stationary phase or a capture substrate disposed on the surfaces thereof. The sample separation apparatus may also include a detector positioned proximate the capillary column. A variation of the sample separation apparatus includes an electrode proximate each end of the capillary column. The sample separation apparatus may be employed to effect various types of chromatographic separation, electrophoretic separation, and analyte identification.
    Type: Grant
    Filed: November 18, 1999
    Date of Patent: October 3, 2006
    Assignee: Micron Technology, Inc.
    Inventor: Terry L. Gilton
  • Patent number: 7105308
    Abstract: Methods are provided for detecting formation of oligomeric complexes of molecules on the surface of cell membranes. These methods employ pairs of tagged probes and cleaving probes, each of which binds specificly to a cell surface molecule. The tagged probe includes a molecular tag that is linked to a first binding compound through a cleavable linkage, and the cleaving probe includes a second binding agent and a cleavage-inducing moiety that can cleave the linkage when within a defined proximity thereto. Binding of the two probes to cell surface molecules that have formed an oligomeric complex results in release of the molecular tag from the binding compound, providing a measure of formation of the complex.
    Type: Grant
    Filed: July 17, 2003
    Date of Patent: September 12, 2006
    Assignee: Monogram Biosciences, Inc.
    Inventors: Po-Ying Chan-Hui, Yining Shi, Sailaja Pidaparthi, Rajiv Dua, Sharat Singh
  • Patent number: 7026002
    Abstract: The invention concerns an element for the determination of an analyte in a liquid by means of a specific binding reaction of two bioaffine binding partners containing in or on material which enables liquid transport between the zones. The element comprises a sample application zone; a detection zone located downstream thereof that is devoid of binding reagents and is the last zone on the element that allows liquid transport; a zone containing immobilized analyte or analyte analogue between the sample application zone and the detection zone; and impregnated conjugate that can be detached by liquid located in the sample application zone or upstream or downstream thereof composed of a bioaffine binding partner capable of a specific binding reaction with the analyte to be determined and a detectable label.
    Type: Grant
    Filed: June 15, 2000
    Date of Patent: April 11, 2006
    Assignee: Roche Diagnostics GmbH
    Inventors: Ada Goerlach-Graw, Reiner Schlipfenbacher
  • Patent number: 6955908
    Abstract: The invention features a biologically pure culture of a newly identified single-celled organism Spiky Rotating Cells (SPR), methods to diagnose an SPR infection in a human patient, an instrument for collecting and detecting an SPR infection, and methods for treating an SPR infection.
    Type: Grant
    Filed: June 21, 2000
    Date of Patent: October 18, 2005
    Inventor: Barbara B. Lambl
  • Patent number: 6949347
    Abstract: The present invention is directed to methods and compositions for determining the presence, absence, and/or amounts of one or more membrane-associated analytes in a sample. In accordance with the invention, binding compounds derivatized with releasable molecular tags specifically bind to selected membrane-associated analytes, after which the molecular tags are released upon activation of cleavage moieties, or sensitizers, anchored in the same membrane as the membrane-associated analytes. The released molecular tags are then identified by their distinct separation and detection characteristics.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: September 27, 2005
    Assignee: Aclara Biosciences, Inc.
    Inventors: Sharat Singh, Po-Ying Chan-Hui
  • Patent number: 6890720
    Abstract: The invention concerns an artificial antigen specifically identified by the anti-filaggrin autoantibodies present in the serum of patients suffering from rheumatoid polyarthritis, and consisting of one polypeptide comprising all or part of the sequence of one filaggrin unit or of a related molecule, in which an arginine radical has been substituted by a citrulline radical. The invention also concerns the use of this antigen for diagnosing rheumatoid polyarthritis.
    Type: Grant
    Filed: September 1, 1997
    Date of Patent: May 10, 2005
    Assignee: Biomerieux
    Inventors: Guy Serre, Elisabeth Girbal-Neuhauser, Christian Vincent, Michel Simon, Mireille Sebbag, Pascal Dalbon, Colette Jolivet-Reynaud, Michel Arnaud, Michel Jolivet
  • Patent number: 6860980
    Abstract: A microchannel device is provided with a plastic substrate having a microchannel formed therein. Polyelectrolyte multilayers are disposed along selected surfaces of the microchannel. The polyelectrolyte layers comprise alternating net positively charged layers and net negatively charged layers. A microchannel lid has a surface facing the microchannel. In making the microchannel device, selected surfaces of the microchannel are alternatively exposed to solutions comprising positively charged polyelectrolytes and negatively charged polyelectrolytes to form the desired number of polyelectrolyte layers.
    Type: Grant
    Filed: June 15, 2001
    Date of Patent: March 1, 2005
    Assignee: The United States of America as represented by the Secretary of Commerce
    Inventors: Laurie E. Locascio, Susan L. R. Barker, David Ross, Michael J. Tarlov
  • Patent number: 6837977
    Abstract: The invention relates to a capillary electrophoresis-based method of screening complex materials for any unidentified affinity ligand that binds to a target of interest. The method subjects a plug of a mixture of the target and a complex material sample, and a separate plug of a known, tight-binding competitive ligand, to capillary electrophoresis under conditions optimized to allow mingling of the two plugs during the capillary electrophoresis run. Preferably, migration of the competitive ligand is tracked.
    Type: Grant
    Filed: June 23, 2000
    Date of Patent: January 4, 2005
    Assignee: Cetek Corporation
    Inventors: Yuriy M. Dunayevskiy, Dallas E. Hughes
  • Publication number: 20040259269
    Abstract: A method for detecting at least one molecular species in a crude sample is disclosed. The method comprises: acquiring a crude sample containing at least one molecular species; separating from the molecular species sample components that have size and masses greater and/or smaller than the molecular species of interest; pre-focusing molecular species in the crude sample within the capillary electrophoresis apparatus one or more times by applying voltage to the capillary for a period of time sufficient to cause electrophoretic migration of at least one molecular species in the sample up to a boundary between a low-electrolyte plug and a high-electrolyte buffer and applying a negative pressure differential to the capillary for a period of time sufficient to cause the pre-focused molecular species to be pushed substantially to its original position; electrophoretically separating the molecular species in the crude sample; and detecting the separated molecular species.
    Type: Application
    Filed: June 20, 2003
    Publication date: December 23, 2004
    Applicant: Groton Biosystems
    Inventors: Shin-Fuw Lin, George E. Barringer
  • Patent number: 6824988
    Abstract: Methods are provided for diagnosing and/or characterizing chronic immune disease activity in a subject. In the subject methods, a sample is obtained from a subject suspected of having or known to have a chronic immune disease. The sample is then assayed for the presence of low molecular actin fragments. The assay results are used to diagnose the presence of chronic immune disease activity and/or characterize chronic immune disease activity in the subject, e.g. to confirm an initial chronic immune disease diagnosis, to determine the stage of the disease, to monitor disease progression, to predict disease attacks, and the like. Also provided by the subject invention are kits for practicing the methods.
    Type: Grant
    Filed: May 15, 2000
    Date of Patent: November 30, 2004
    Assignee: R.E.D. Laboratories, N.V.
    Inventors: Simon Adriaan Michiel Roelens, Patrick Englebienne, Anne Marie Yvonne Robert D'Haese, C. V. Taylor Herst
  • Patent number: 6818409
    Abstract: A method for separating and purifying HA-positive progenitor toxin(s) (LL and/or L toxins) and HA-negative progenitor toxin (M toxin) from a Clostridium botulinum strain is provided. The method comprises applying a liquid containing both the HA-positive progenitor toxin(s) and the HA-negative progenitor toxin to a lactose column. Also provided is a method for separating and purifying neurotoxin (7S toxin) from HA-positive progenitor toxins, which comprises treating HA-positive progenitor toxins with an alkaline buffer and then applying the resulting liquid containing dissociated neurotoxin and non-toxic components to a lactose column. Activated pure HA-positive toxins (L and LL toxins) and neurotoxin are obtained by simple procedures.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: November 16, 2004
    Assignees: Eisai Company Ltd., Keiji Oguma
    Inventor: Kenji Oguma
  • Patent number: 6812033
    Abstract: The invention provides a method for identifying patients with normal NCEP lipid levels who are in need of treatment for cardiovascular disease comprising measuring one or more LDL or HDL particle subclass levels and identifying abnormal LDL or HDL subclass levels.
    Type: Grant
    Filed: April 12, 2002
    Date of Patent: November 2, 2004
    Assignee: Berkeley HeartLab, Inc.
    Inventors: David Shewmake, Frank Ruderman, Christopher Boggess